Drugs / TPIV200
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02978222 | Jul 2017 → Jan 2020 | ovarian cancer | Marker Therapeutics, Inc. | Terminated | Missed primary |
| Phase 2 | NCT02764333 | May 2016 → Jan 2021 | ovarian cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-11-12 | Marker Therapeutics, Inc. | Results Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results markertherapeutics.com ↗
Marker will be discontinuing the development of TPIV200 in patients with platinum-sensitive advanced ovarian cancer based on an unblinded review of interim results from its Phase 2 study conducted by an independent Data and Safety Monitoring Board (DSMB). |
| 2019-01-03 | Marker Therapeutics, Inc. | Results Marker Therapeutics Provides Updates of its Lead Clinical Programs markertherapeutics.com ↗
Reports interim immunogenicity findings of TPIV200 Phase II study in triple negative breast cancer |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-11-12 | Marker Therapeutics, Inc. | Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results markertherapeutics.com ↗ |
| 2019-01-03 | Marker Therapeutics, Inc. | Marker Therapeutics Provides Updates of its Lead Clinical Programs markertherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPIV200 | “We conducted a randomized, double-blind, multicenter, phase II study to evaluate the safety and efficacy of TPIV200 (a multi-epitope FRα peptide vaccine admixed with GM-CSF)...” PMID 39068739 ↗ Jul 2024 |
| Known as | TPIV200/huFR-1 | “TPIV200/huFR-1 (also called TPIV200), which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF” NCT02764333 ↗ |
| Modality | Vaccine | “which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF” NCT02764333 ↗ |
| Route | Other | “Patients were vaccinated intradermally once every 4 weeks up to 6 times” PMID 39068739 ↗ Jul 2024 |